Revolutionary, minimally invasive cardiac support device and mitral valve repair technology.
A less invasive procedure, improved quality of life and reduced risk of complications. These are some of the advantages of Prof. Jan Otto Solem’s invention - an entirely new approach to the support of the cardiac function in patients with severe heart failure. The technology is applicable to a growing worldwide demographic of more than one million heart failure patients.
60% of stroke volume is due to the up-and-down movement of the atrioventricular plane. The Syntach CS device restores impaired movement of the atrioventricular plane and naturally supports the heart. It is a permanent, active implant that can be implanted using minimally invasive transcatheter techniques. Syntach CS smaller than existing left ventricular assist devices (LVADs) and is therefore suitable for both men and women of all sizes.
Syntach´s products are being developed and have not yet been approved for clinical use.
Minimally Invasive
Fully Implantable
Integrated
Patient
Monitoring
Low Patient
Risk
Small
Device
Wireless Recharging
Syntach AB ("Syntach") is pleased to announce that the Company’s Syntach Cardiac Support system (Syntach CS) has been selected for an oral presentation in the Best Innovation Competition to be held during the CRT 2023 annual meeting taking place at the Omni Shoreham Hotel in Washington DC, February 25 - 28, 2023. The Syntach technology also qualifies for the CRT 2023 Top Innovation Award. The winner announcement will be made at the FDA Town Hall Luncheon on Tuesday, February 28th, 2023.
Syntach AB ("Syntach") is pleased to announce that it has entered into a partnership agreement with Meditrial Europe Ltd ("Meditrial") to support the clinical and regulatory strategies of Syntach’s innovative minimally invasive cardiac support system …
Swedish medtech startup Syntach AB has been awarded up to €15 million in equity financing by European Innovation Council (EIC) for the development of the Syntach Cardiac Support System, a breakthrough device for patients with heart failure …
We are a rapidly expanding company and constantly looking for experienced, skilled and motivated personnel. If you are interested in joining our team please send your application to work@syntach.com.
Syntach AB
Postal address: Box 4004, SE-227 21 Lund, Sweden
Visiting address: Traktorvägen 6C, SE-226 60 Lund, Sweden
+46 46 270 87 55
info@syntach.com
Syntach´s products are under development and not approved for clinical use.
© Syntach AB. All rights reserved. Syntach is a registered trademark. Privacy and cookie policy.
THT 2023 (March 20–22, Boston, MA)
Syntach has been nominated for the “Shark Tank Competition” at THT 2023.
www.tht2023.crfconnect.com
Contact, Patrick Schnegelsberg to arrange a meeting or for more information.
Deny
OK
We use cookies to improve your experience. By using the site, you agree that cookies are used for this purpose. Please see our privacy policy for details.
